Literature DB >> 10794522

Differential upregulation of p53-responsive genes by genotoxic stress in hematopoietic cells containing wild-type and mutant p53.

B Gong1, A Almasan.   

Abstract

Cells respond to genotoxic stress by activation of many genes, including the tumor suppressor p53. p53 activates transcriptionally target genes, such as p21waf1 and gadd45, which can lead to cell cycle arrest, or bax, which can lead to cell death. We examined the response to genotoxic stress in two hematopoietic cell lines that harbor either wild-type (MOLT-4) or a mutant p53 with a codon 161 mutation (U266). We adapted a multiprobe RNase protection assay (RPA) to determine the steady-state RNA levels, and in combination with nuclear runoff assays, transcriptional rates of multiple stress-induced genes. We found a differential activation of growth arrest and cell death-specific p53 target genes in cells with wild-type or mutant p53. Our results show that genotoxic stress can activate the p21waf1 and gadd45 genes in both cell lines. However, the bax gene was not induced in U266 cells. Bax and gadd45 gene induction could be efficiently blocked by pretreating the cells with the antioxidant compound pyrrolidine dithiocarbamate, suggesting that oxidative stress was involved in these responses. Induction of all three genes in MOLT-4 cells was clearly at the transcriptional level, because we detected transcriptional activity by nuclear runoff RPA assays, and transfection with a consensus p53 binding sequence. U266 cells did not activate the same reporter, in spite of the upregulation of p21waf1 and gadd45 RNA levels. However, the p21waf1-reporter constructs containing 0.9 to 2.4 kb of the native p21 promoter were potently activated in U266 cells. These results indicate a differential regulation of p53 target genes in cells containing wild-type or codon 161 mutant p53.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10794522      PMCID: PMC6157362     

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  38 in total

1.  Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest.

Authors:  V Reinke; G Lozano
Journal:  Radiat Res       Date:  1997-08       Impact factor: 2.841

Review 2.  The p53 network.

Authors:  M L Agarwal; W R Taylor; M V Chernov; O B Chernova; G R Stark
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

3.  A model for p53-induced apoptosis.

Authors:  K Polyak; Y Xia; J L Zweier; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1997-09-18       Impact factor: 49.962

4.  Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis.

Authors:  Q Zhan; S Fan; I Bae; C Guillouf; D A Liebermann; P M O'Connor; A J Fornace
Journal:  Oncogene       Date:  1994-12       Impact factor: 9.867

5.  Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation.

Authors:  Y Xiong; H Zhang; D Beach
Journal:  Genes Dev       Date:  1993-08       Impact factor: 11.361

6.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  Induction of p21 (WAF-1/CIP1) during differentiation.

Authors:  R A Steinman; B Hoffman; A Iro; C Guillouf; D A Liebermann; M E el-Houseini
Journal:  Oncogene       Date:  1994-11       Impact factor: 9.867

Review 8.  Transcriptional regulation of the p21((WAF1/CIP1)) gene.

Authors:  A L Gartel; A L Tyner
Journal:  Exp Cell Res       Date:  1999-02-01       Impact factor: 3.905

9.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

Authors:  V Dulić; W K Kaufmann; S J Wilson; T D Tlsty; E Lees; J W Harper; S J Elledge; S I Reed
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

Review 10.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

View more
  6 in total

1.  High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.

Authors:  H A F Stessman; A Lulla; T Xia; A Mitra; T Harding; A Mansoor; C L Myers; B G Van Ness; N G Dolloff
Journal:  Leukemia       Date:  2014-07-09       Impact factor: 11.528

2.  Paradoxical effects of a stress signal on pro- and anti-apoptotic machinery in HTLV-1 Tax expressing cells.

Authors:  Cynthia de la Fuente; Lai Wang; Dai Wang; Longwen Deng; Kaili Wu; Hong Li; L Dana Stein; Thomas Denny; Frederick Coffman; Kylene Kehn; Shanese Baylor; Anil Maddukuri; Anne Pumfery; Fatah Kashanchi
Journal:  Mol Cell Biochem       Date:  2003-03       Impact factor: 3.396

3.  Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma.

Authors:  Q Chen; B Gong; A S Mahmoud-Ahmed; A Zhou; E D Hsi; M Hussein; A Almasan
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

4.  Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.

Authors:  Jens G Lohr; Sora Kim; Joshua Gould; Birgit Knoechel; Yotam Drier; Matthew J Cotton; Daniel Gray; Nicole Birrer; Bang Wong; Gavin Ha; Cheng-Zhong Zhang; Guangwu Guo; Matthew Meyerson; Andrew J Yee; Jesse S Boehm; Noopur Raje; Todd R Golub
Journal:  Sci Transl Med       Date:  2016-11-02       Impact factor: 17.956

Review 5.  Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma.

Authors:  Quan Chen; Subrata Ray; Mohamad A Hussein; Gordan Srkalovic; Alexandru Almasan
Journal:  Leuk Lymphoma       Date:  2003-07

6.  The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.

Authors:  Kimberley L Kaufman; Yiping Jenkins; Munther Alomari; Mehdi Mirzaei; O Giles Best; Dana Pascovici; Swetlana Mactier; Stephen P Mulligan; Paul A Haynes; Richard I Christopherson
Journal:  Oncotarget       Date:  2015-12-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.